Journal
JOURNAL OF IMMUNOLOGY
Volume 187, Issue 5, Pages 2072-2078Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1100762
Keywords
-
Categories
Funding
- European Union [260687]
- Reprogramming the Immune System for Establishment of Tolerance network
- Deutsche Forschungsgemeinschaft [GE-1188/1-1]
- MRC [G0801537] Funding Source: UKRI
- Medical Research Council [G0801537, G0600698B] Funding Source: researchfish
Ask authors/readers for more resources
Regulatory macrophages (M regs) were administered to two living-donor renal transplant recipients. Both patients were minimized to low-dose tacrolimus monotherapy within 24 wk of transplantation and subsequently maintained excellent graft function. After central venous administration, most M regs remained viable and were seen to traffic from the pulmonary vasculature via the blood to liver, spleen, and bone marrow. By 1 y posttransplantation, both patients displayed patterns of peripheral blood gene expression converging upon the IOT-RISET signature. Furthermore, both patients maintained levels of peripheral blood FOXP3 and TOAG-1 mRNA expression within the range consistent with nonrejection. It is concluded that M regs warrant further study as a potential immune-conditioning therapy for use in solid-organ transplantation. The results of this work are being used to inform the design of The ONE Study, a multinational clinical trial of immuno-modulatory cell therapy in renal transplantation. The Journal of Immunology, 2011, 187: 2072-2078.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available